Pharmaceutical Technology on MSN
Genmab to acquire Merus shares for $8bn
The key asset in this acquisition is Merus' EGFRxLGR5 bispecific antibody, petosemtamab, currently in Phase III development.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback